Viriom donates Elpida to Chinese and Russian governments for experimental use against COVID-19; also working with global health authorities to determine the efficacy and safety of Elpida and its other clinical candidates AV5080, AV5124 and AV5126 against COVID-19
SAN DIEGO, March 24, 2020 /PRNewswire/ -- Viriom Inc today announces the company's activities to address the COVID-19 public health crisis, including supporting the experimental use of the HIV medicine, Elpida (elsulfavirine) and Viriom's experimental flu medicines AV5080, AV5124 and AV5126 to determine their efficacy in the treatment of COVID-19.
The company is collaborating with Chinese Center for Disease Control and Prevention and the Ministry of Health in Russia and select health authorities and institutions in US and globally to determine the antiviral activity of Elpida and several other drug candidates against COVID-19. Viriom is evaluating Chinese and Russian claims that Elpida could be effective in COVID-19 treatment.
Along with industry partners from China Medical Systems Holdings, Insilico Medicines in Hong Kong and Molsoft in San Diego, Viriom is collaborating with PLA Military Academy and Zhejiang University in China, ChemRar Group, Gamaleya Research Institute of Epidemiology and Microbiology, Research Center Institute of Immunology in Russia, Osang Healthcare in South Korea to support research of targeted medicines with novel mechanisms of action against COVID-19 and other pathogenic RNA viruses.
"We are committed to address the COVID-19 public health crisis, which is why we responded quickly to Chinese and Russian authorities' request for Elpida and other drugs testing in February," said Nikolay Savchuk, chairman and president, Viriom. "We are working with global health authorities to ensure we meet the need of COVID-19 patients, conduct the appropriate non clinical and clinical trials to evaluate its efficacy and ensure uninterrupted supply of Elpida for HIV patients around the world."
Viriom has supplied Elpida and AV5080, AV5124 and AV5126 candidates as an experimental option to test and apply for the treatment of COVID-19 to multiple countries. The company plans to continue to respond to all appropriate requests for product while supporting all efforts to determine the safety and efficacy of these medicines and candidate medicines in this patient population. Viriom will maintain the supply of Elpida for HIV patients and will increase supply for COVID-19 patients.
About Viriom:
Viriom Inc (San Diego, CA) focuses on the treatment, prophylaxis, and eradication of infectious diseases globally. Viriom is developing and commercializing the most innovative and affordable solutions to radically expand global access to the best antiviral treatments. Viriom's broad, proprietary, and partnered pipeline covers therapeutic, prophylactic, and curative medicines for HIV, viral hepatitis, flu coronaviruses and other pathogenic infectious diseases. Learn more at www.viriom.com
About Elpida® (elsulfavirine): Elsulfavirine is an investigational new drug that is being studied in once daily and once weekly oral long-acting formulations to treat HIV infection. Elsulfavirine was approved for treating HIV in Russia and Kazakhstan and has been submitted to obtain marketing approvals in multiple countries in South East and East Asia, and Latin America. Elsulfavirine belongs to a group of HIV drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs). Studies have shown that elsulfavirine appears effective for treating HIV in people who have not previously taken HIV medicines. Elsulfavirine may be effective against certain strains of HIV that can no longer be controlled by Food and Drug Administration (FDA)-approved NNRTIs or other viral infections. Viriom is also developing a long-acting injectable formulation of investigational new drug VM1500A-LAI to prevent and treat HIV.
Media Contact (s): Iain Dukes, PhD, CEO Viriom Inc, [email protected]
SOURCE Viriom
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article